Search

Your search keyword '"Balkis Meddeb"' showing total 3 results
Start Over Author "Balkis Meddeb" Journal mediterranean journal of hematology and infectious diseases
3 results on '"Balkis Meddeb"'

1. TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN

Author

Ramzi Jeddi, Hèla Ghédira, Ramzi Ben Amor, Yosr Ben Abdennebi, Kacem Karima, Zarrouk Mohamed, Hend Ben Neji, Lamia Aissaoui, Raihane Ben Lakhal, Naouel Ben Salah, Samia Menif, Zaher Belhadjali, Hela Ben Abid, Emna Gouider, Raouf Hafsia, Ali Saad, Pierre Fenaux, and Balkis Meddeb

Subjects
Leukemia, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

In Tunisia, the ATRA era began in 1998 with the use, consecutively, of two regimens combining ATRA and an anthracycline with cytarabine (APL93), and without cytarabine (LPA99). From 2004, 51 patients with confirmed APL either by t(15;17) or PML/RARA were treated according to the PETHEMA LPA 99 trial. Forty three patients achieved CR (86%). The remaining seven patients had early death (one died before treatment onset): four caused by differentiation syndrome (DS) and three died from central nervous system hemorrhage. Multivariate analysis revealed that female gender (P=0.045), baseline WBC> 10 G/L ( P=0.041) and serum creatinine > 1.4mg/dl ( P=0.021) were predictive of mortality during induction. DS was observed in 16 patients (32%) after a median onset time of 15 days from treatment onset (range, 2–29). Body mass index ≥ 30 (P=0.01) was the only independent predictor of DS. Occurrence of hypertensive peaks significantly predicted occurrence of DS (P=0.011) and was significantly associated with high BMI (p=0.003). With a median follow-up of 50 months, 5 year cumulative incidence of relapse, event free and overall survival were 4.7%, 74% and 78%, respectively.

Published
2011
Full Text
View/download PDF

2. TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN

Author

Hela Ben Abid, Zaher Belhadjali, Samia Menif, Naouel Ben Salah, Raihane Ben Lakhal, Lamia Aissaoui, Hend Ben Neji, Zarrouk Mohamed, Kacem Karima, Yosr Ben Abdennebi, Ramzi Ben Amor, Hèla Ghédira, Ramzi Jeddi, Emna Gouider, Raouf Hafsia, Ali Saad, Pierre Fenaux, and Balkis Meddeb

Subjects
Leukemia, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

In Tunisia, the ATRA era began in 1998 with the use, consecutively, of two regimens combining ATRA and an anthracycline with cytarabine (APL93), and without cytarabine (LPA99). From 2004, 51 patients with confirmed APL either by t(15;17) or PML/RARA were treated according to the PETHEMA LPA 99 trial. Forty three patients achieved CR (86%). The remaining seven patients had early death (one died before treatment onset): four caused by differentiation syndrome (DS) and three died from central nervous system hemorrhage. Multivariate analysis revealed that female gender (P=0.045), baseline WBC> 10 G/L ( P=0.041) and serum creatinine > 1.4mg/dl ( P=0.021) were predictive of mortality during induction. DS was observed in 16 patients (32%) after a median onset time of 15 days from treatment onset (range, 2–29). Body mass index ≥ 30 (P=0.01) was the only independent predictor of DS. Occurrence of hypertensive peaks significantly predicted occurrence of DS (P=0.011) and was significantly associated with high BMI (p=0.003). With a median follow-up of 50 months, 5 year cumulative incidence of relapse, event free and overall survival were 4.7%, 74% and 78%, respectively.

Published
2011

3. TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN

Author

Yosr Ben Abdennebi, Ali Saad, Zaher Belhadjali, Hela Ben Abid, Kacem Karima, Ramzi Ben Amor, Hela Ghedira, Ramzi Jeddi, Pierre Fenaux, Zarrouk Mohamed, Naouel Ben Salah, Raihane Ben Lakhal, Balkis Meddeb, Emna Gouider, Hend Ben Neji, Lamia Aissaoui, Raouf Hafsia, and Samia Menif

Subjects
Acute promyelocytic leukemia, medicine.medical_specialty, Creatinine, Leukemia, Anthracycline, business.industry, lcsh:RC633-647.5, Hematology, lcsh:Diseases of the blood and blood-forming organs, medicine.disease, Gastroenterology, chemistry.chemical_compound, Regimen, Infectious Diseases, chemistry, Internal medicine, Immunology, medicine, Cytarabine, Cumulative incidence, business, Body mass index, medicine.drug
Abstract

In Tunisia, the ATRA era began in 1998 with the use, consecutively, of two regimens combining ATRA and an anthracycline with cytarabine (APL93), and without cytarabine (LPA99). From 2004, 51 patients with confirmed APL either by t(15;17) or PML/RARA were treated according to the PETHEMA LPA 99 trial. Forty three patients achieved CR (86%). The remaining seven patients had early death (one died before treatment onset): four caused by differentiation syndrome (DS) and three died from central nervous system hemorrhage. Multivariate analysis revealed that female gender (P=0.045), baseline WBC> 10 G/L ( P=0.041) and serum creatinine > 1.4mg/dl ( P=0.021) were predictive of mortality during induction. DS was observed in 16 patients (32%) after a median onset time of 15 days from treatment onset (range, 2–29). Body mass index ≥ 30 (P=0.01) was the only independent predictor of DS. Occurrence of hypertensive peaks significantly predicted occurrence of DS (P=0.011) and was significantly associated with high BMI (p=0.003). With a median follow-up of 50 months, 5 year cumulative incidence of relapse, event free and overall survival were 4.7%, 74% and 78%, respectively.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results